Other approaches include whole cell vaccine based methods that use autologous tumor cells expressing an anti-sense to TGFβ2 [280] or tumor-specific CD8 + T cells modified to express a dominant-negative TGFβRII (non- ovarian cancers) [279]. The gene discussed is CD8A; the disease is neoplasm.